source
- Kardigan extends biotech’s streak of big IPOs with $400M haulIncluding the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.BioPharma Dive · 1mo ago↗ source
- Kardigan raises $400M in IPO to back three clinical-stage cardio drugsMore evidence has arrived that biotech IPOs are alive and well: A cardiology drug developer with three clinical-stage candidates just secured $400 million for its Nasdaq debut slated for Thursday.…Endpoints · 1mo ago↗ source
- Biogen makes up to $1B deal for secretive anti-inflammatory biotechBiogen will pay as much as $1 billion — “predominantly” in milestone payments — to acquire a San Diego biotech that has disclosed little about its pipeline. The startup, RayThera, debuted last year…